On April 23, 2026, the FDA reclassified twelve compounded peptides — including BPC-157, TB-500, ipamorelin, and several others on the GH-axis and recovery panels. Same week, Limitless committed publicly on /why-physician-led to a specific operational standard: two qualified 503A compounding pharmacy partners under written agreement no later than June 1, 2026, with the audit checklist published, redundancy in supply, and chain-of-custody documentation for every dose dispensed to a Limitless patient.
This page exists so anyone — a patient, a future regulator, a competitor — can see where that commitment actually stands at any point in time. We update it within 48 hours of any material change.
Two additional 503A pharmacies have been identified as backups in case Partner A or B fails the audit or declines to sign. These remain unnamed publicly until and unless engaged, to avoid premature association on either side.
We are using a three-color status convention on this page:
In the interim — until Partner A is signed — Limitless is operating from a single qualified 503A pharmacy under a verbal handshake plus initial paperwork. This is sufficient for the small founding-member cohort currently on protocol (six patients as of this writing), but it is the redundancy gap that the two-partner commitment exists to close.
Two practical impacts for current patients:
1. No protocol change is required pending Partner A or B signing. Current GH-axis recommendations (tesamorelin lead, sermorelin alternative, ipamorelin conditional) are unchanged.
2. Once Partner B is signed, patients who prefer a specific compounding pharmacy can request the assignment at no cost. Patients are not required to switch — but the option will be available.
Questions about your specific protocol or pharmacy assignment should be sent directly to Dr. Hare: hare.joshua42@gmail.com.